Physician profile
David B Herring
NPI 1336640788
$2,156.71
in general payments reported to CMS, 2019-2025
29 companies · $872 in 2025
The $872 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.96 · 2022: $576 · 2023: $96.75 · 2024: $589 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $291.15 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $286.59 | 2022-2025 | |
| Novo Nordisk INC | $211.53 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $177.80 | 2021-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $141.20 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.74 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $110.07 | 2024-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.44 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $70.55 | 2024-2025 | Trelegy Ellipta, Bexsero, Penmenvy |
| Eisai INC. | $63.20 | 2024-2025 | |
| Dexcom, INC. | $61.69 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $55.62 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $54.24 | 2022-2025 | Trintellix |
| Biogen, INC. | $50.18 | 2024-2025 | Leqembi |
| Exact Sciences Corporation | $42.49 | 2024 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $34.64 | 2024-2025 | Nuzyra |
| Lundbeck LLC | $32.52 | 2022-2025 | Rexulti |
| Renalytix Ai, INC. | $29.93 | 2022 | |
| Abbott Laboratories | $28.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.42 | 2024 | |
| Axsome Therapeutics, INC. | $22.96 | 2024 | Auvelity |
| Pfizer INC. | $22.71 | 2024 | |
| Mylan Specialty L.P. | $22.51 | 2022 | |
| Ironwood Pharmaceuticals, INC | $20.72 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.45 | 2025 | Voquezna |
| Amgen INC. | $15.16 | 2025 | Repatha, Otezla |
| Verona Pharma, INC. | $15.03 | 2025 | Ohtuvayre |
| Nestle Healthcare Nutrition INC. | $13.89 | 2022 | |
| Genentech USA, INC. | $9.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.